mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, Pradip K, Febbo, Phillip G, Bikoff, Rachel, Berger, Raanan, Xue, Qi, McMahon, Louis M, Manola, Judith, Brugarolas, James +5 more·2004·Nature Medicine
DOI 10.1038/nm1052

Cited by (962)

Items 801–900 of 962

  1. Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer
    Andrew Erich Teschendorff, Linlin Li, Zhen Yang · 2015 · Genome biology
  2. Peritoneal Membrane Injury and Peritoneal Dialysis
    Shaan Chugh, Sultan Chaudhry, Timothy Ryan, Peter J. Margetts · 2014 · Advances in Nephrology
  3. PTEN in Prostate Cancer
    Marcus A. Ruscetti, Hong Wu · 2013 · Springer eBooks
  4. Genetically Engineered Mouse Models of Prostate Cancer
    Martijn C. Nawijn, Andreas M. Bergman, Henk G. van der Poel · 2008 · European Urology Supplements
  5. EHD1 promotes breast cancer metastasis through upregulating HIF2a expression via activating mTOR pathway
    Xiaoqian Gao, Juan Li, Xuefei Feng, Yuchen Xie, Juan Zhang, Pengfei Liu, Bo Wang, Peijun Liu · 2024 · The FASEB Journal
  6. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes
    Rong Liu, Wei Zhang, Zhaoqian Liu, Hong‐Hao Zhou · 2016 · Oncotarget
  7. Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts.
    Yuefeng Du, Qingzhi Long, Ying Shi, Xiao-Gang Liu, Xudong Joshua Li, Jin Zeng, Yong‐Guang Gong, Xinyang Wang, Dalin He · 2013 · Europe PMC (PubMed Central)
  8. Sulfathiazole treats type 2 diabetes by restoring metabolism through activating CYP19A1
    Zhuozhou Hu, Chun Li, Tongyu Wu, Jing Zhou, Liang Han, Jingjing Liu, Shaojia Qiang, Wenyang Zhao, Xiangxiang Li, Xiaohua Liu et al. · 2023 · Biochimica et Biophysica Acta (BBA) - General Subjects
  9. Effet antitumoral des inhibiteurs du signal de prolifération
    Jérôme Dumortier · 2009 · Gastroentérologie Clinique et Biologique
  10. Evaluation of mTOR function by a gain-of-function approach
    Yoichiro Ohne, Terunao Takahara, Tatsuya Maeda · 2009 · Cell Cycle
  11. Cancer Chemoprevention
    Christopher Hanyoung Lieu, William N. William, Scott Michael Lippman · 2010 · Springer eBooks
  12. Expression genomics and cancer biology
    Edison T. Liu · 2004 · Pharmacogenomics
  13. In vitro innate immune stimulation using beta-glucan in head kidney adherent macrophage-like cells derived from rohu, Labeo rohita
    David Waikhom, Laishram Soniya Devi, Janmejay Parhi, Tanmoy Gon Choudhury, Sagar Chandra Mandal · 2025 · Comparative Immunology Reports
  14. Activating KRAS mutations mark premalignant cystic structures in congenital pulmonary airway malformations
    Cathy van Horik, Floor Benthem, Marjon Buscop‐van Kempen, Anne Boerema‐de Munck, Wilfred F. J. van IJcken, Rene M. H. Wijnen, Johannes Marco Schnater, Robbert J. Rottier · 2026 · Respiratory Research
  15. The mTOR Complexes in Cancer Cell Metabolism
    Thomas P. Lynch, Joseph Gennaro Moloughney, Estela Jacinto · 2016 · Cancer drug discovery and develogment/Cancer drug discovery and development
  16. RETRACTED: Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization
    Gloria Pedot, Joana Graca Marques, Philip P. Ambühl, Marco Wachtel, Stephanie Kasper, Quy Ai Ngo, Felix K Niggli, Beat W. Schäfer · 2022 · Neoplasia · Retracted
  17. Identification of autophagy and angiogenesis modulators in colorectal cancer based on bioinformatics analysis
    Fariba Shakeri, Parisa Mohamadynejad, Mehdi Moghanibashi · 2023 · Nucleosides Nucleotides & Nucleic Acids
  18. Cell Biology of Prostate Cancer and Molecular Targets
    Martin Edwin Gleave, Michael Cox, Yuzhuo Z. Wang · 2010 · Springer eBooks
  19. Molecular Pathology of the Genitourinary Tract: Molecular Pathology of Kidney and Testes
    Sahussapont Joseph Sirintrapun, Anil Vasdev Parwani · 2009 · Surgical pathology clinics
  20. The Hypoxia-Inducible Factor-1α in Angiogenesis and Cancer: Insights from the Drosophila Model
    Vasilia Tamamouna, Chrysoula Pitsouli · 2018 · InTech eBooks
  21. Expression genomics and cancer drug development
    Edison T. Liu · 2004 · Drug Development Research
  22. Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC
    Brittany Bahamón, Sabina Signoretti · 2012 · Springer eBooks
  23. HIF-1-regulated glucose metabolism in the control of apoptosis signaling
    Simone Fulda · 2008 · Expert Review of Endocrinology & Metabolism
  24. Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
    Alessandro Porrello, Roberto Piergentili · 2015 · Current Genomics
  25. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis
    Pedro Coelho Barata, Cristina Magi‐Galluzzi, Ruby Gupta, Robert Dreicer, Eric A. Klein, Jorge Alberto Garcia · 2019 · Clinical Genitourinary Cancer
  26. AKT
    Matı́as Blaustein · 2017 · Springer eBooks
  27. Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
    Attalla Farag El-kott, Eman R. ElBealy, Fahmy G. Elsaid, Haitham Ibrahim El-Mekkawy, Abd-El-karim Mohamed Abd-Lateif, Abdulali Taweel, Heba S. Khalifa, Ahmad Y Kandeel, Kareem Morsy, Essam Hassan Ibrahim et al. · 2021 · Biocell
  28. Aging-associated mechanisms and metabolic vulnerabilities in esophageal carcinoma: an integrative review
    Qiwei Liu, Zhiyu Xie, Wei Li, Mengxiang Li, Yijun Qi · 2025 · Frontiers in Cell and Developmental Biology
  29. Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation
    Qiao Zeng, Jie Ying Chen, Han Zhang, Wenying Yu, Haonan Xu, Qiao Wang, Zhan Tang · 2025 · International Journal of Nanomedicine
  30. The Role of PI3K/AKT/HIF‐1α Pathway in the Effect of Nano‐TiO2 on Lactate Production in TM4 Cells
    Hongmei Chang, Siqi Zhao, Yuzhu Lei, Yunhua Hu, Yizhong Yan, Guanling Song · 2024 · Journal of Applied Toxicology
  31. Complex interaction of adipokines in breast cancer and anti-tumour immunity; a new paradigm for cancer treatment
    Peng Tan, Mingrui Xie, Eleftherios Sfakianakis · 2021 · Cancer Research and Cellular Therapeutics
  32. Lomitapide repurposing for treatment of malignancies: A promising direction
    Hua-Tao Wu, Bingxuan Wu, Ze-Xuan Fang, Zheng Lai Wu, Yan-Yu Hou, Yu Deng, Yukun Cui, Jing Liu · 2024 · Heliyon
  33. Zaburzenia metabolizmu i funkcji enzymów metabolicznych a proces nowotworzenia
    Elzbieta A. Sarnowska, M. Leszczynski, Ewelina Macech-Klicka, Malgorzata Stachowiak, JANUSZ ALEKSANDER SIEDLECKI · 2016 · Nowotwory Journal of Oncology
  34. The Cell Cycle and Androgen Signaling Interactions in Prostate Cancer
    Simone de Brot, Nigel Patrick Mongan · 2017 · Molecular pathology library
  35. Cancer Chemoprevention
    Scott Michael Lippman, J. Jack Lee · 2008 · Elsevier eBooks
  36. MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER+ Breast Cancer
    Janine Wörthmüller, Simona Disler, Sylvain Pradervand, François Richard, Lisa Haerri, Gustavo A. Ruiz Buendía, Nadine Fournier, Christine Desmedt, Curzio Rüegg · 2023 · Cells
  37. Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
    Hua Cai, Rongrong Zheng, Ningxia Wu, Jiaman Hu, Ruixin Wang, Jianing Chi, Wei Zhang, Linping Zhao, Hong Bo Cheng, Ali Chen et al. · 2023 · Pharmaceutics
  38. Inhalational Anesthetic Agents and Their Effects on Cancer Cell Biology
    Nicholas J. S. Perry, Daqing Ma · 2015 · Current anesthesiology reports
  39. Mouse Models in Cancer Research
    Soyoung Lee, Clemens A. Schmitt · 2006 · Wiley eBooks
  40. Cancer Chemoprevention
    Scott Michael Lippman, J. Jack Lee · 2015 · Elsevier eBooks
  41. Precision Fishing for Enzyme-like Materials: Identifying and Engineering Mesoporous Catalytic Sites for Ferroptosis Induction
    Wenjie Li, David Panáček, Qianqian Xie, Huilin Chen, Qing Kun Yang, Maomao Xie, Di Wu, Xiaoming Cai, Ivan Dědek, Zengli Zhang et al. · 2025 · Nano Letters
  42. β-Sitosterol Enhances the Anticancer Efficacy of Oxaliplatin in COLO-205 Cells via Apoptosis and Suppression of VEGF-A, NF-κB-p65, and β-Catenin
    Sahar Khateeb, Fahad M. Almutairi, Adel I. Alalawy, Amnah Obidan, Mody Albalawi, Rehab F. Al-Massabi, Hanan Abdulrahman Sagini, Samah Sulaiman Abuzahrah, Eman F. S. Taha · 2025 · International Journal of Molecular Sciences
  43. Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation
    G‐One Ahn, J. Martin Brown · 2006 · Springer eBooks
  44. THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN AND KIDNEY CANCER
    William G. Kaelin, Boston Ma · 2007 · Medicina-buenos Aires
  45. Where Statistics and Molecular Microarray Experiments Biology Meet
    Diana Kelmansky · 2013 · Methods in molecular biology
  46. The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities
    Boyang Jason Wu, Leland W.K. Chung · 2016 · Cancer drug discovery and develogment/Cancer drug discovery and development
  47. PI3K pathway in cancer
    Amancio Carnero · 2015 · Cambridge University Press eBooks
  48. The Role of Mammalian Target of Rapamycine Signaling Pathway in Central Nervous System Cancers: A Review
    Forough Alemi Serej, Hosein Aliyari Serej, Abbas Ebrahimi Kalan, Ahmad Mehdipour, Zeynab Aliyari Serej, Balal Bravan, Mohammad Reza Shiri‐Shahsavar · 2020 · The Journal of Qazvin University of Medical Sciences
  49. Tumor cell metabolism and autophagy as therapeutic targets
    Satish S. Poojary, Mukul Kumar Singh · 2022 · Elsevier eBooks
  50. Regulation and dysregulation of protein synthesis in cancer cells
    Michael J. Clemens, Androulla Elia, Simon Morley · 2015 · Cambridge University Press eBooks
  51. Genome-based approaches for the diagnosis of breast cancer: a review with perspective
    Dimosthenis E. Ziogas · 2014 · Breast Cancer Management
  52. Cellular and Molecular Signatures of Androgen Ablation of Prostate Cancer
    Clifford G. Tepper, Hsing-Jien Kung · 2009 · Springer eBooks
  53. Predictive Biomarkers of Response to mTOR Inhibitors
    Sandrine J. Faivre, Cindy Neuzillet, Éric Raymond · 2015 · Springer eBooks
  54. Metabolomic-Based Stratification in Prostate Cancer
    Stefano Cacciatore, Giorgia Zadra, Massimo F. Loda · 2017 · Molecular pathology library
  55. PTEN
    Lloyd C. Trotman · 2010 · Elsevier eBooks
  56. Autophagy in cancer: friend or foe?
    Silvia Vega-Rubín-de-Celis · 2021 · Elsevier eBooks
  57. Comprehensive molecular portraits of human breast tumours
    Richard A. Moore, Lucinda Fulton, Martin Hirst, Hye-Jung E. Chun, Robert S. Fulton, Elaine R. Mardis, Noreen Dhalla, Adrian Ally, Daniel C. Koboldt, David J. Dooling et al. · 2020 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  58. Senescence in aging
    Sofie Lautrup, Alexander S. Anisimov, Mariá José Lagartos-Donate, Evandro Fei Fang · 2022 · Elsevier eBooks
  59. Role of PI3K–Akt and PTEN in the Growth and Progression of Prostate Cancer
    Haojie Huang, Donald J. Tindall · 2008 · Humana Press eBooks
  60. Hypoxia-Inducible Factor 1 in the Angiogenesis of Prostate Cancer
    Jonathan W. Simons · 2008 · Humana Press eBooks
  61. Irinotecano ativa a via PI3-quinase/AKT/mTOR em linhagem de adenocarcinoma de colon
    Kellen K. Souza · 2007
  62. HIF‐1 Inhibitors for Cancer Therapy
    Annamaria Rapisarda, Giovanni Melillo · 2010 · Wiley eBooks
  63. Genetic Alterations in Prostate Cancer
    Evan Y. Yu, William C. Hahn · 2005 · Clinical Prostate Cancer
  64. Studies on the PI3K/mTOR pathway as cytostatic treatment target in pituitary adenomas
    Vesna Cerovac · 2010 · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)
  65. Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer
    Madlaina Breuleux, Heidi A. Lane · 2009 · Humana Press eBooks
  66. Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells
    Carly C. Barron · 2012 · Brock University Digital Repository (Brock University)
  67. Under Normoxia Simvastatin Shifts Lipid Metabolism of B16.F10 Melanoma Cells to Support Their Aggressiveness
    Giorgiana Negrea, Loredana Bălăcescu, Alina Sesărman, Manuela Banciu · 2024 · Preprints.org
  68. Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer
    Jonathan E. Rosenberg · 2010 · Springer eBooks
  69. PDGFRb regulation as a mode of resistance to EGFR inhibition in Glioblastoma
    David Akhavan · 2012 · eScholarship (California Digital Library)
  70. Functional networks of events that modulate phenotypic manifestation of cancer
    Sam Thiagalingam · 2015 · Cambridge University Press eBooks
  71. Análise do perfil de expressão gênica de linhagens epiteliais mamárias humanas submetidas ao tratamento com rapamicina associada à doxorrubicina
    Adriana Priscila Trapé · 2011
  72. Highlights of Natural Products in Prostate Cancer Drug Discovery
    Jorge A. R. Salvador, M. Vania · 2011 · InTech eBooks
  73. Investigating the Regulation and Potential Role of Nonhypoxic Hypoxia-Inducible Factor 1 (HIF-1) in Aromatase Inhibitor Resistant Breast Cancer
    Armina A. Kazi · 2012
  74. Targeting the Phosphoinositide‐3‐kinase/Akt/Mammalian Target of Rapamycin Pathway
    Courtney A. Granville, Regan Michelle Memmott, Joell J. Gills, Phillip A. Dennis · 2006 · Wiley eBooks
  75. Optimierung der Therapie des metastasierten Mammakarzinoms unter besonderer Berücksichtigung des Pi3K/Akt/mTOR-Signaltransduktionswegs
    Jan Eucker · 2013 · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
  76. Angiogenesis "in vitro" of the healthy mouse heart under hypoxia : the role of Angiotensin II and Nitric Oxide
    Veronica C. Munk · 2005 · edoc (University of Basel)
  77. Regulation of Translation in Malignant Transformation
    Michael J. Clemens · 2007 · Wiley eBooks
  78. Co-Targeting Therapeutics for Hormone Refractory Prostate Cancer
    Vasily J. Assikis · 2007 · Humana Press eBooks
  79. Sirolimus liposomal formulations for targeting of cancer tumours
    Ichioma Onyesom · 2014 · Greenwich Academic Literature Archive (University of Greenwich)
  80. Combinations of Cytotoxic Drugs, Ionizing Radiation, and Mammalian Target of Rapamycin (mTOR) Inhibitors
    Jann Nagina Sarkaria · 2006 · Springer eBooks
  81. An Integrated Oncogenomic Approach: From Genes to Pathway Analyses
    Jeffrey A. Klomp, Bin Tean Teh, Kyle A. Furge · 2009 · Springer eBooks
  82. Caracterização da transmissão do sinal da insulina e da leptina em hipotalamo de roedores durante a anorexia induzida pelo cancer
    Eduardo Rochete Ropelle · 2010
  83. Everolimus for renal cell carcinoma: predictive factors for response and future directions
    Guru Sonpavde, Thomas E. Hutson · 2009 · Medical Oncology
  84. Combination therapy for renal cell carcinoma: review of the clinical evidence
    David F. McDermott, Keith T. Flaherty · 2011 · Clinical Investigation
  85. RapTOR strikes again
    Nicola McCarthy · 2004 · Nature reviews. Cancer
  86. Endocrine regulation of prostate cancer growth
    Zoran Čulig · 2006 · Expert Review of Endocrinology & Metabolism
  87. ROLE OF MANGANESE SUPEROXIDE DISMUTASE IN CHEMOTHERAPY- INDUCED OXIDATIVE STRESS
    Heather L. Gustafson · 2011 · UA Campus Repository (The University of Arizona)
  88. Short Title: GL/FFA Cycle and Signaling
    Marc Prentki, S.R. Murthy Madiraju · 2008
  89. Aspects biologiques de la cancérogenèse : quelles cibles pour la prévention ? Biological aspects of cancerogenesis: which targets for the prevention? Mots-clés : Cancer du sein - Prévention - Marqueur biologique - SERM - Anti-aromatase - Anti-facteur de croissance - Anti-inflammatoire - Vaccination - Habitudes alimentaires. Keywords: Breast cancer - Prevention - Biological marker - SERM - Aromatase inhibitor - Anti-growth factor - Anti-inflammatory drug - Vaccination - Nutrition.
    Thierry Maudelondé, Catherine Desmetz, Jérôme Solassol · 2008
  90. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
    Jianqing Lin, Aileen Deng, Jean H. Hoffman-Censits, Geoffrey Thomas Gibney, Terry Hyslop, Brooke Miller, Deborah L. Kilpatrick, Serge A Jabbour, William Kevin Kelly · 2015 · Cancer Treatment Communications
  91. Targeted Therapy in Prostate Cancer
    Amado J. Zurita, John Francis Ward, Jeri Kim · 2008 · Humana Press eBooks
  92. mTOR Pathway in Renal Cell Carcinoma
    Matteo Santoni, Francesco Massari · 2016 · Elsevier eBooks
  93. Phosphoproteomic Investigation of Differential Signalling Downstream of Class IA PI3K Isoforms.
    Michael Hartley Walsh · 2014 · Queen Mary Research Online (Queen Mary University of London)
  94. The Molecular Pathogenesis and Pathophysiology of Prostate Cancer
    William G. Nelson, Angelo Michael De Marzo · 2016 · CRC Press eBooks
  95. Effect of Akt (PKB) on the activity of mammalian target of rapamycin (mTOR)
    Annett Hahn-Windgassen · 2005
  96. Mechanistic Analysis of Differential Signal Transduction Mediated by the Insulin Receptor Substrate Proteins IRS-1 and IRS-2: A Dissertation
    Justine Landis · 2014 · eScholarship@UMassChan
  97. Combination Therapies Targeting the PI3K/AKT/mTOR Pathways
    Aung Naing, Gordon Brent Mills, Funda Meric‐Bernstam · 2016 · Cancer drug discovery and develogment/Cancer drug discovery and development
  98. Alterations in the regulatory networks of cellular and molecular events
    Sam Thiagalingam · 2015 · Cambridge University Press eBooks
  99. Positron Emission Tomography Imaging of Platinum Resistant Ovarian Cancer And Drug Modulation
    Meg Perumal · 2012
  100. Genetic Evidence For Neuron-Glia Metabolic Coupling In The CNS
    Lotti M. Supplie · 2016